RomiDEPsin
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 795 publications
Histone and non-histone protein acetylation in a tail regeneration model (Ambystoma mexicanum).
Journal: Biology open
Published: June 01, 2026
Consensus transcriptional signature of dengue virus infection reveals coordinated interferon suppression and stress-response activation.
Journal: Cell biochemistry and biophysics
Published: May 07, 2026
Hypophosphatemia as a Potential Class Effect of Histone Deacetylase Inhibitors: Evidence from Disproportionality Analysis and Mendelian Randomization Analysis of Drug Targets.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: March 31, 2026
Ford JG, Koh MJ, Lenart AW, et al. Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas. Blood Adv. 2025;9(16):4286-4305.
Journal: Blood advances
Published: January 29, 2026
Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database.
Journal: Journal of pharmaceutical health care and sciences
Published: January 27, 2026
Cardiac HDAC3 Disruption Contributes to HDAC Inhibitor-Induced QT Prolongation.
Journal: Cells
Published: January 01, 2026
Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells.
Journal: Bioorganic chemistry
Published: December 27, 2025
Data-Driven Drug Discovery Optimization for Breast Cancer Using Interpretable Machine Learning Models.
Journal: Journal of visualized experiments : JoVE
Published: September 29, 2025
Last Updated: 06/30/2026